A Randomized, Active-Controlled, Open-Label, Flexible-Dose Study to Assess the Safety and Tolerability of Topiramate as Monotherapy Compared With Levetiracetam as Monotherapy in Pediatric Subjects With New or Recent-Onset Epilepsy

Trial Profile

A Randomized, Active-Controlled, Open-Label, Flexible-Dose Study to Assess the Safety and Tolerability of Topiramate as Monotherapy Compared With Levetiracetam as Monotherapy in Pediatric Subjects With New or Recent-Onset Epilepsy

Recruiting
Phase of Trial: Phase III

Latest Information Update: 06 Dec 2017

At a glance

  • Drugs Topiramate (Primary) ; Levetiracetam
  • Indications Epilepsy; Partial epilepsies; Tonic-clonic epilepsy
  • Focus Adverse reactions; Registrational
  • Sponsors Janssen Research & Development; Janssen-Cilag
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 20 Apr 2017 Planned End Date changed from 1 Mar 2018 to 26 Mar 2019.
    • 28 Sep 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top